Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Metastatic ER-Positive HER2-Negative Breast Cancer Novel Treatment Combination Improves Progression-Free Survival

ADC Improves Outcomes for Patients With Advanced TNBC Ineligible for Immunotherapy

RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition

Belzutifan Achieves Durable Responses Without Surgery in Advanced Pheochromocytoma Paraganglioma

VT3989 Demonstrates Antitumor Activity and Tolerability in Refractory Mesothelioma